BELMONT, Mass.--(BUSINESS WIRE)--Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, today announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing its total funding in equity and grants to $42 million. Investors included Neuro.VC, Byers Capital, and others. The company's initial program is a neu